Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 9Terminated 8Recruiting 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Genitourinary 2Gastrointestinal 2Dermatologic 2Breast 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1CNS 1

Conditions

Melanoma 8Leukemia, Myeloid, Acute 6Breast Neoplasms 6Colorectal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Skin Neoplasms 3Mesothelioma, Malignant 3Lymphoma, Non-Hodgkin 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Stomach Neoplasms 2Sarcoma 2Recurrence 2Rectal Neoplasms 2Pleural Effusion, Malignant 2Neuroblastoma 2Neoplasms 2Multiple Myeloma 2Lung Neoplasms 2Leukemia, Myeloid 2Leukemia 2Head and Neck Neoplasms 2Glioblastoma 2Esophageal Neoplasms 2Carcinoma, Merkel Cell 2Urinary Bladder Neoplasms 1Turcot syndrome 1

Interventions

pembrolizumab 38Blood Specimen Collection 38Bevacizumab 22Surveys and Questionnaires 18Standard of Care 18Radiotherapy 17Exercise 17Carboplatin 17Nivolumab 15atezolizumab 14Paclitaxel 14Cisplatin 14Drug Therapy 13Fluorouracil 12Cyclophosphamide 12Cetuximab 11Trastuzumab 10Pemetrexed 10Leucovorin 10Docetaxel 10Dexamethasone 10Oxaliplatin 9Biopsy 9pertuzumab 8olaparib 8Temozolomide 8Panitumumab 8Observation 8Irinotecan 8abemaciclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Neoplasms × Interleukin-2 × Clear all
NCT07410494 2026-02-18

SELECT-CAR-NK

Essen Biotech

Phase 1/2 Recruiting
85 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT05086692 2025-07-09

ABILITY-1

Medicenna Therapeutics, Inc.

Phase 1/2 Recruiting
115 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡